NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis ; volume:38 ; number:5 ; year:2015 ; pages:221-229
Oncology research and treatment ; 38, Heft 5 (2015), 221-229
- Creator
-
Kurbacher, Christian M.
Fietz, Thomas
Diel, Ingo J.
Egert, Matthias
Hurtz, Hans-Jürgen
Lück, Andreas
Weide, Rudolf
Salat, Christoph
Wolff, Thomas
Zaiss, Matthias
Klare, Peter
Losem, Christoph
Illmer, Thomas
WeißEnborn, Georg
Steffens, Claus-Christoph
Schulze, Matthias
Tesch, Hans
Oskay-Oezcelik, Gülten
Teichmann, Beate
Harde, Johanna
Scheuerlein, Robert Willy
- DOI
-
10.1159/000381631
- URN
-
urn:nbn:de:101:1-2017120814778
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:19 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kurbacher, Christian M.
- Fietz, Thomas
- Diel, Ingo J.
- Egert, Matthias
- Hurtz, Hans-Jürgen
- Lück, Andreas
- Weide, Rudolf
- Salat, Christoph
- Wolff, Thomas
- Zaiss, Matthias
- Klare, Peter
- Losem, Christoph
- Illmer, Thomas
- WeißEnborn, Georg
- Steffens, Claus-Christoph
- Schulze, Matthias
- Tesch, Hans
- Oskay-Oezcelik, Gülten
- Teichmann, Beate
- Harde, Johanna
- Scheuerlein, Robert Willy
Other Objects (12)
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
Nadir
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases
Nadir
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study
Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients
Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
Nurses’ knowledge of chemotherapy-induced neutropenia and its management: a cross-sectional survey
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases